MTR and neoplasm: In line with this assumption, by using a xenograft tumor model, we found that the xenograft tumor growth induced by MTR loss and MTHFD2 overexpression could be abrogated by administering the serine metabolism inhibitor NCT503 (which targets the key serine metabolism enzyme PHGDH46) (Fig. 3l, m).